In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Yield of targeted AF screening in a high-risk cohort with chronic kidney disease, diabetes mellitus and cardiovascular disease

Session Poster session 2

Speaker Piotr Sobocinski-Doliwa

Event : EHRA 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Prevalence and Incidence of Atrial Fibrillation
  • Session type : Poster Session

Authors : P Sobocinski-Doliwa (Stockholm,SE), JM Corander (Stockholm,SE), M Rosenqvist (Stockholm,SE), J Spaak (Stockholm,SE)

P Sobocinski-Doliwa1 , JM Corander1 , M Rosenqvist1 , J Spaak1 , 1Karolinska Institute, Danderyd Hospital, Department of Clinical Sciences - Stockholm - Sweden ,

European Heart Journal Supplements ( 2018 ) 20 ( Supplement 1 ), i163

Background/introduction: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an estimated prevalence of 3 %. The prevalence increases with age and is higher in subgroups with various comorbidities such as Chronic Kidney Disease (CKD) and Diabetes Mellitus (DM). CKD and DM also increase the risk of thromboembolic events.  Screening programs in older unselected patients (75-76 years) have shown to yield about 3 % new, previously untreated AF diagnoses.

Purpose: Targeted screening for AF in a high-risk population of AF naïve, CKD patients with concomitant DM and cardiovascular disease

Methods: At Danderyd University Hospital, a specialized outpatient clinic has been developed, treating patients with combined CKD, cardiovascular disease and DM. A previous review of the patient cohort followed up at this clinic has shown an AF prevalence of 47 %.

The remaining patients (n=108), of the above group treated at the outpatient clinic were invited to participate in an AF screening study. Inclusion criteria were: manifest cardiovascular disease, DM and CKD, defined as macro-albuminuria or an estimated GFR < 60 ml/min/1.73m2. Patients were instructed to perform 30 second ECG registrations 2-4 daily for 14 days, using an ambulatory hand held ECG recording device. Patients with detected AF during follow-up were informed and offered oral anti coagulant treatment.

Results: Median age of 71 years (29- 88) and 43 % were female. In 4% of the screened patients previously undiagnosed AF was detected. In patients > 65 years the prevalence was 7 %. OAC treatment was accepted in all patients with new AF. The mean CHA2DS2-VASc score for the AF group was 4.6 and the HAS-BLED score 3.0.

Conclusion: The AF prevalence is high in this patient group with a combination of CKD, diabetes and cardiovascular disease. The high AF prevalence and overall high risk-scores may pose an increased risk for stroke.  This may indicate that AF screening in these patients is motivated.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are